These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35981243)

  • 1. Glycoproteomics Identifies Plexin-B3 as a Targetable Cell Surface Protein Required for the Growth and Invasion of Triple-Negative Breast Cancer Cells.
    Kuhlmann L; Govindarajan M; Mejia-Guerrero S; Ignatchenko V; Liu LY; Grünwald BT; Cruickshank J; Berman H; Khokha R; Kislinger T
    J Proteome Res; 2022 Sep; 21(9):2224-2236. PubMed ID: 35981243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.
    Zhen Y; Zhao R; Wang M; Jiang X; Gao F; Fu L; Zhang L; Zhou XL
    Theranostics; 2020; 10(18):8080-8097. PubMed ID: 32724459
    [No Abstract]   [Full Text] [Related]  

  • 3. Comprehensive proteomics and sialiomics of the anti-proliferative activity of safranal on triple negative MDA-MB-231 breast cancer cell lines.
    Zarrineh M; Ashrafian S; Jensen P; Nawrocki A; Ansari AM; Rezadoost H; Ghassempour A; Larsen MR
    J Proteomics; 2022 May; 259():104539. PubMed ID: 35240313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer.
    Camorani S; Hill BS; Collina F; Gargiulo S; Napolitano M; Cantile M; Di Bonito M; Botti G; Fedele M; Zannetti A; Cerchia L
    Theranostics; 2018; 8(18):5178-5199. PubMed ID: 30429893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
    Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
    J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chloroform Fraction of Methanolic Extract of Seeds of Annona muricata Induce S Phase Arrest and ROS Dependent Caspase Activated Mitochondria-Mediated Apoptosis in Triple-Negative Breast Cancer.
    Kariyil BJ; Ayyappan UPT; Gopalakrishnan A; George AJ
    Anticancer Agents Med Chem; 2021; 21(10):1250-1265. PubMed ID: 32951586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cancer-testis gene,
    Gu Y; Wang C; Zhu R; Yang J; Yuan W; Zhu Y; Zhou Y; Qin N; Shen H; Ma H; Wang H; Liu X; Hu Z
    Cancer Biol Med; 2021 Feb; 18(1):74-87. PubMed ID: 33628586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of ERK5 targeting in triple negative breast cancer.
    Ortiz-Ruiz MJ; Álvarez-Fernández S; Parrott T; Zaknoen S; Burrows FJ; Ocaña A; Pandiella A; Esparís-Ogando A
    Oncotarget; 2014 Nov; 5(22):11308-18. PubMed ID: 25350956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles.
    Kannan A; Philley JV; Hertweck KL; Ndetan H; Singh KP; Sivakumar S; Wells RB; Vadlamudi RK; Dasgupta S
    Sci Rep; 2019 Aug; 9(1):11632. PubMed ID: 31406142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel.
    Guo P; Yang J; Huang J; Auguste DT; Moses MA
    Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18295-18303. PubMed ID: 31451668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LRP8 is overexpressed in estrogen-negative breast cancers and a potential target for these tumors.
    Maire V; Mahmood F; Rigaill G; Ye M; Brisson A; Némati F; Gentien D; Tucker GC; Roman-Roman S; Dubois T
    Cancer Med; 2019 Jan; 8(1):325-336. PubMed ID: 30575334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.
    Cheung A; Opzoomer J; Ilieva KM; Gazinska P; Hoffmann RM; Mirza H; Marlow R; Francesch-Domenech E; Fittall M; Dominguez Rodriguez D; Clifford A; Badder L; Patel N; Mele S; Pellizzari G; Bax HJ; Crescioli S; Petranyi G; Larcombe-Young D; Josephs DH; Canevari S; Figini M; Pinder S; Nestle FO; Gillett C; Spicer JF; Grigoriadis A; Tutt ANJ; Karagiannis SN
    Clin Cancer Res; 2018 Oct; 24(20):5098-5111. PubMed ID: 30068707
    [No Abstract]   [Full Text] [Related]  

  • 14. Proliferation-associated long noncoding RNA, TMPO-AS1, is a potential therapeutic target for triple-negative breast cancer.
    Mitobe Y; Ikeda K; Sato W; Kodama Y; Naito M; Gotoh N; Miyata K; Kataoka K; Sasaki H; Horie-Inoue K; Inoue S
    Cancer Sci; 2020 Jul; 111(7):2440-2450. PubMed ID: 32437068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
    M-Rabet M; Cabaud O; Josselin E; Finetti P; Castellano R; Farina A; Agavnian-Couquiaud E; Saviane G; Collette Y; Viens P; Gonçalves A; Ginestier C; Charafe-Jauffret E; Birnbaum D; Olive D; Bertucci F; Lopez M
    Ann Oncol; 2017 Apr; 28(4):769-776. PubMed ID: 27998973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs).
    Orr K; Buckley NE; Haddock P; James C; Parent JL; McQuaid S; Mullan PB
    Oncotarget; 2016 Aug; 7(34):55458-55472. PubMed ID: 27487152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
    Peck B; Bland P; Mavrommati I; Muirhead G; Cottom H; Wai PT; Maguire SL; Barker HE; Morrison E; Kriplani D; Yu L; Gibson A; Falgari G; Brennan K; Farnie G; Buus R; Marlow R; Novo D; Knight E; Guppy N; Kolarevic D; Susnjar S; Milijic NM; Naidoo K; Gazinska P; Roxanis I; Pancholi S; Martin LA; Holgersen EM; Cheang MCU; Noor F; Postel-Vinay S; Quinn G; McDade S; Krasny L; Huang P; Daley F; Wallberg F; Choudhary JS; Haider S; Tutt AN; Natrajan R
    Cancer Res; 2021 Feb; 81(4):847-859. PubMed ID: 33509944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative breast cancer cell line sensitivity to englerin A identifies a new, targetable subtype.
    Grant CV; Carver CM; Hastings SD; Ramachandran K; Muniswamy M; Risinger AL; Beutler JA; Mooberry SL
    Breast Cancer Res Treat; 2019 Sep; 177(2):345-355. PubMed ID: 31230251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.
    Jovanović B; Beeler JS; Pickup MW; Chytil A; Gorska AE; Ashby WJ; Lehmann BD; Zijlstra A; Pietenpol JA; Moses HL
    Breast Cancer Res; 2014 Jul; 16(4):R69. PubMed ID: 24985072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.